Dr. Ryan Cassaday, M.D.
Hematology & Oncology (Hematology & Oncology Physician)
825 Eastlake Ave E
Seattle, WA 98109
Who else practices at this address →
King County includes primary care (5% of residents) and dental (4% of residents) and mental health (4% of residents) shortage areas. About shortage areas
- Medicare participating
At a glance
- Years since graduation
- 19
- In the NPI registry since
- 2007
- Medicare patients seen, 2024
- 66
Licensed in Washington since 2010, according to the Washington State Department of Health. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2007Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Hematology & Oncology Physician primary
WA license MD60158445 (first issued 2010; active) -
Internal Medicine Physician
WA license MD60158445 (first issued 2010; active)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- University of Washington Medical Ctr Seattle, WA
Medical groups
- The Association of University Physicians (3,535 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 66
- Services billed
- 284
- Patients’ average age
- 71
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 40-54 minutes | 156 | 59 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | 62 | 11 |
| Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | 21 | 12 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Prednisone Other prescribers in Seattle, WA | 18 |
| Acyclovir Other prescribers in Seattle, WA | 12 |
| Ursodiol Other prescribers in Seattle, WA | 12 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 7 companies reported 13 payments worth $16,073 in total to this clinician.
| Autolus Inc | $5,391 |
|---|---|
| Pfizer Inc. | $3,700 |
| Servier Pharmaceuticals LLC | $2,800 |
| Merck Sharp & Dohme LLC | $2,471 |
| AstraZeneca Pharmaceuticals LP | $1,640 |
| Amgen Inc. | $49.98 |
| Novartis Pharmaceuticals Corporation | $20.18 |
| Consulting Fee | $6,680 |
|---|---|
| Honoraria | $5,130 |
| Compensation for services other than consulting (speaking, faculty) | $3,700 |
| Food and Beverage | $413 |
| Travel and Lodging | $150 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Pfizer Inc. Jun 18, 2025 | Compensation for services other than consulting (speaking, faculty) BOSULIF · METABOLIC DISEASE;ONCOLOGY · in-kind Company’s descriptionNo payment was made directly to this author. This is a fair market value payment for editorial or medical writing services paid to a 3rd-party vendor to assist with the development of a publication. | $3,700 |
| Servier Pharmaceuticals LLC Nov 10, 2025 | Consulting Fee Asparlas · Oncology | $2,800 |
| Autolus Inc Dec 9, 2025 | Honoraria | $2,565 |
| Autolus Inc Dec 9, 2025 | Honoraria in-kind | $2,565 |
| Merck Sharp & Dohme LLC Dec 15, 2025 | Consulting Fee | $2,240 |
| AstraZeneca Pharmaceuticals LP Nov 5, 2025 | Consulting Fee | $1,640 |
| Merck Sharp & Dohme LLC Dec 15, 2025 | Travel and Lodging travel to Orlando, FL | $150 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 5 industry-funded studies in 2025, from 5 companies. The companies reported $14,788,448 in research payments for these studies, mostly to the institutions running them.
- A Phase 1/2 Open-label Study to Investigate the Safety, Efficacy, and Pharmacokinetics of Administration of Subcutaneous Blinatumomab for the Treatment of Adults and Adolescents With Relapsed or Refractory B Cell Prec…
Amgen Inc. - Dose-Adjusted EPOCH Rituximab +Tafasitamab for the Treatment of Newly-Diagnosed Adults with Philadelphia chromosomenegative B-cell LymphoblasticLymphoma/Leukemia
Incyte Corporation - Calaspargase pegol in adults with all
Servier Bioinnovation - A Phase 1/2 Study to Evaluate the Safety and Efficacy of AZD0486 in Adolescent and Adult Participants with Relapsed or Refractory B-Cell Acute Lymphoblastic Leukaemia
AstraZeneca Pharmaceuticals LP - Tolerability study of VTR-297 in subjects with relapsed or refractory hematologic malignancies
Vanda Pharmaceuticals Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.